Abstract
Preclinical laboratory science has revealed multiple new targets for breast cancer therapy. Clinical trials targeting key signaling pathways are underway and a number of new drugs have been approved for treatment. Targeting of growth factor receptors by monoclonal antibodies and tyrosine kinase inhibitors were among the first to be approved, but new small molecules inhibiting the phosphatidylinositol 3-kinase signaling pathway have also shown promise. This review will evaluate potential new targets and specifically targets in hormone receptor positive and triple negative breast cancer.
Keywords: Breast cancer, estrogen receptor, growth factor receptors, mammalian target of rapamycin, phosphatidylinositol 3-kinase, tyrosine kinase inhibitors.
Current Cancer Therapy Reviews
Title:New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Volume: 11 Issue: 4
Author(s): John P. Schwerkoske and Douglas Yee
Affiliation:
Keywords: Breast cancer, estrogen receptor, growth factor receptors, mammalian target of rapamycin, phosphatidylinositol 3-kinase, tyrosine kinase inhibitors.
Abstract: Preclinical laboratory science has revealed multiple new targets for breast cancer therapy. Clinical trials targeting key signaling pathways are underway and a number of new drugs have been approved for treatment. Targeting of growth factor receptors by monoclonal antibodies and tyrosine kinase inhibitors were among the first to be approved, but new small molecules inhibiting the phosphatidylinositol 3-kinase signaling pathway have also shown promise. This review will evaluate potential new targets and specifically targets in hormone receptor positive and triple negative breast cancer.
Export Options
About this article
Cite this article as:
P. Schwerkoske John and Yee Douglas, New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151215220005
DOI https://dx.doi.org/10.2174/1573394712666151215220005 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Structural Requirements of Heparin and Related Molecules to Exert a Multitude of Anti-Inflammatory Activities
Mini-Reviews in Medicinal Chemistry The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C
Current Drug Metabolism Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Synthesis of Metronidazole Derivatives Containing Pyridine Ring and Anticancer Activity
Letters in Organic Chemistry The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Genotoxicity of Nanocarriers
Current Drug Metabolism Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An In Vitro/ In Vivo Study
Anti-Cancer Agents in Medicinal Chemistry 64Cu Labeled AmBaSar-RGD2 for micro-PET Imaging of Integrin αvβ3 Expression
Current Radiopharmaceuticals Electrochemical Nano-biosensors as Novel Approach for the Detection of Lung Cancer-related MicroRNAs
Current Molecular Medicine Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity
Anti-Cancer Agents in Medicinal Chemistry Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design